Institute for Genome Sciences and Policy, Duke University, Durham, NC 27708, USA.
Annu Rev Genomics Hum Genet. 2010;11:383-425. doi: 10.1146/annurev-genom-082509-141811.
Genomics and human genetics are scientifically fundamental and commercially valuable. These fields grew to prominence in an era of growth in government and nonprofit research funding, and of even greater growth of privately funded research and development in biotechnology and pharmaceuticals. Patents on DNA technologies are a central feature of this story, illustrating how patent law adapts-and sometimes fails to adapt-to emerging genomic technologies. In instrumentation and for therapeutic proteins, patents have largely played their traditional role of inducing investment in engineering and product development, including expensive post-discovery clinical research to prove safety and efficacy. Patents on methods and DNA sequences relevant to clinical genetic testing show less evidence of benefits and more evidence of problems and impediments, largely attributable to university exclusive licensing practices. Whole-genome sequencing will confront uncertainty about infringing granted patents, but jurisprudence trends away from upholding the broadest and potentially most troublesome patent claims.
基因组学和人类遗传学在科学上具有基础性,在商业上具有价值。这些领域在政府和非营利性研究资金增长的时代以及生物技术和制药领域私人资助的研究和开发增长更为显著的时代崭露头角。DNA 技术专利是这一故事的核心特征,说明了专利法如何适应(有时未能适应)新兴的基因组技术。在仪器和治疗性蛋白方面,专利在很大程度上发挥了其传统作用,即鼓励对工程和产品开发进行投资,包括昂贵的发现后临床研究,以证明安全性和有效性。与临床基因检测相关的方法和 DNA 序列专利的证据表明,其益处较少,问题和障碍较多,这主要归因于大学的排他性许可做法。全基因组测序将面临侵犯已授予专利的不确定性,但判例法趋势是不支持最广泛和最可能引起麻烦的专利主张。